EMA acts to improve quality of Type IA variation submissions
This article was originally published in SRA
The European Medicines Agency is taking steps to improve the quality of applications submitted by pharmaceutical companies seeking to make minor changes (Type IA variations) to their marketing authorisations1. To this end, the EMA has developed a "pre-notification checklist" to help companies submit correct and complete Type IA variation notifications2.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.